Skip to content

Allphase Pharma Consulting, LLC

A Professional Service Provider for the Pharma Industry

Allphase Pharma Consulting, LLC
Menu
Secondary Menu

Primary menu

  • CONTACT
  • BLOGS
    • The Viewpoint
    • The News
    • Recent Literature
    • Did you know…?
    • QIDP Antibiotics
  • LEGAL
  • WELCOME

Secondary menu

  • The News
  • The Viewpoint
  • Did you know…?
  • Recent Literature
  • QIDP Antibiotics

Tag Archives: curative vs. chronic

It’s Not a Free-Enterprise Market, Stupid!

Posted on September 26, 2014 by Harald — No Comments ↓

The economics of developing antibacterials is a frustrating topic to address.  There are unique aspects to the antibiotic market which sets it apart from other medicines, esp. the unique societal aspects of antibiotic use which go beyond the benefit to Continue reading It’s Not a Free-Enterprise Market, Stupid!→

Share this:

  • Click to share on LinkedIn (Opens in new window) LinkedIn
  • Click to share on Facebook (Opens in new window) Facebook
  • Click to share on X (Opens in new window) X
  • Click to print (Opens in new window) Print
  • Click to email a link to a friend (Opens in new window) Email

Like this:

Like Loading...
Posted in Recent Literature, The Viewpoint | Tagged '10 x '20 initiative, acute vs chronic, antibiotic marketing, antibiotic resistance, antibiotic value, Bayer, Coartem, Cubist, curative vs. chronic, economic incentives for industry, FDA, ice bucket challenge, IDSA, ivermectin, malaria, market economy, market forces, Merck, moxifloxacin, MTB, Novartis, onchocerciasis, orphan drug pathway, regulated market, societal impact of antibiotics, tuberculosis, veterinary use of antibiotics | Leave a reply

Primary Sidebar Widget Area

Posts and Blogs

  • COMPARISON OF BAFF / APRIL INHIBITORS – 2
  • COMPARISON OF BAFF / APRIL INHIBITORS
  • TELITACICEPT IN SLE
  • The Antifungal Landscape – 2
  • The Antifungal Landscape – 1
  • About DIPHTHERIA
  • Draft FDA Guidance for COCCIDIOIDOMYCOSIS
  • HANSA, Where is the Beef?
  • OLOROFIM in a TIGHT SPOT
  • Prof Brambell’s FcRn – The Story So Far

Subscribe to AllphasePharma Blogs via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Tags

ABSSSI Achaogen Allphase Pharma Consulting aminoglycoside antibiotic blog Avycaz Bayer CABP Ceftazidime/avibactam cIAI ciprofloxacin colistin Cubicin Cubist cUTI dalbavancin Dalvance daptomycin delafloxacin eravacycline FDA fosfomycin GSK Harald Reinhart levofloxacin Merck meropenem moxifloxacin MRSA Novartis omadacycline oritavancin P. aeruginosa Pfizer PK/PD plazomicin QIDP solithromycin tedizolid tetracycline Tetraphase tigecycline Tygacil vancomycin VAP

Footer menu

  • CONTACT
  • BLOGS
  • LEGAL
  • WELCOME
  • Email
Copyright © 2025 Allphase Pharma Consulting, LLC. All Rights Reserved.
Theme: Catch Box by Catch Themes
Scroll Up
%d